We observed that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes characterize advanced CML disease and poor imatinib respondents. This evidence concerns the gene DAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive.